Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: Feasibility and toxicity

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 3, 2003, Pages 312-316

  Oh, William K ^a   Kaplan, Irving D ^b   Febbo, Philip ^a   Prisby, Judith ^a   Manola, Judith ^a   Kaufman, Donald S ^c   Kantoff, Philip W ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Chemotherapy; Neoadjuvant; Prostate cancer

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; DOXORUBICIN; GONADORELIN DERIVATIVE; LEUPRORELIN; LIPOSOME; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG FORMULATION; HIGH RISK PATIENT; HUMAN; MALE; MALE GENITAL TRACT CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE ENDORECTAL COIL; SKIN TOXICITY; TREATMENT OUTCOME;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANILIDES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; DOXORUBICIN; HUMANS; LEUPROLIDE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0037841351     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200306000-00021     Document Type: Article

References (17)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Oh WK, Kantoff PW. Treatment of locally advanced prostate cancer: is chemotherapy the next step? J Clin Oncol 1999;17: 3664-75.
3. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
4. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
5. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71(suppl 3):1098-109.
6. Newling DW. The use of adriamycin and its derivatives in the treatment of prostatic cancer. Cancer Chemother Pharmacol 1992; 30(suppl):S90-4.
7. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92.
8. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995;13:1777-85.
9. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19;424-36.
10. Goebel FD, Goldstein D, Goos M, et al. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. Br J Cancer 1996;73: 989-94.
11. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15:987-93.
12. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000;89:1037-47.
13. Vaage J, Barbera-Guillem E, Abra R, et al. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994;73:1478-84.
14. Pettaway CA, Pisters LL, Troncoso P, et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 2000;18:1050-7.
15. Oh WK, George DJ, Kaufman DS, et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high risk localized prostate cancer: a preliminary report. Semin Oncol 2001; 28(suppl 15):40-4.
16. Hubert A, Lyass O, Pode D, et al. Doxil (Caelyx). An exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 2000;11:123-7.
17. Mamounas EP, Fisher B. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol 2001:28:389-99.